US Patent

US10098845 — Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof

Method of Use · Assigned to Impax Laboratories LLC · Expires 2034-10-07 · 8y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a controlled release oral formulation of levodopa and/or its esters, used in combination with a decarboxylase inhibitor.

USPTO Abstract

The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.

Drugs covered by this patent

Sinemet Cr (CARBIDOPA) · Aton

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-219`	—	Sinemet Cr
`U-219`	—	Sinemet Cr
`U-219`	—	Sinemet Cr
`U-219`	—	Sinemet Cr

Patent Metadata

Patent number: US10098845
Jurisdiction: US
Classification: Method of Use
Expires: 2034-10-07
Drug substance claim: No
Drug product claim: Yes
Assignee: Impax Laboratories LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.